Evidence map›Paper›PMID 41279346›Full record

ArticlebioRxiv : the preprint server for biology2025

Base editing and nanoparticle transfection of airway cell types essential for treatment of cystic fibrosis.

Erin W Kavanagh, Anya T Joynt, Audrey R Pion, Alice C Eastman, Alianna I Parr, Katherine L Starego, Manav Jain, Sydney R Shannon, Edwin Yoo, Gregory A Newby and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Erin W KavanaghDepartment of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-8206-3923
Anya T JoyntDepartment of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Audrey R PionDepartment of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Alice C EastmanDepartment of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Alianna I ParrDepartment of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Katherine L StaregoDepartment of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Manav JainDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205, USA.
Sydney R ShannonDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205, USA.
Edwin YooDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205, USA.
Gregory A NewbyDepartment of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-7869-2615
Stephany Y TzengDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0002-7561-482X
Neeraj SharmaDepartment of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Jordan J GreenDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0003-4176-3808
Garry R CuttingDepartment of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-8250-8590

Funding

TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Jordan Green, JONATHAN P SCHNECK · 2019 to 2026
$11.5M
A PLATFORM TECHNOLOGY TO GENETICALLY REPROGRAM CANCER CELLS FOR ENHANCED IMMUNOTHERAPYR37CA246699 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZENG, STEPHANY YI · 2020 to 2025
$2.6M
Suprachoroidal nonviral gene transfer of engineered VEGF antagonistsR01EY031097 · NEI · JOHNS HOPKINS UNIVERSITY · PI CAMPOCHIARO, PETER A, GREEN, JORDAN · 2020 to 2023
$2.4M
NCI NIH HHS R37 CA246699NEI NIH HHS R01 EY031097NIBIB NIH HHS P41 EB028239
6 · The paper itself

Abstract

Cystic Fibrosis (CF) is a life-limiting genetic disorder caused by deleterious variants in the

Indexed as

base editingCRISPR-Cas9cystic fibrosisGene editingnanoparticlesscRNA-seq

Identifiers

PMID41279346
PMCPMC12637497

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.